Table 2 Antiretroviral therapy data of patients in cohort
Characteristics | Total patients (n = 1904) | Prevalent TB at baseline | p-value | |
|---|---|---|---|---|
No | Yes | |||
Total patients, n (%) | 1904 (100%) | 1267 (66.5%) | 637 (33.5%) | Â |
ART regimes (n = 1894)b, n (%) | 0.947 | |||
 NNRTI based | 1482 (78.2%) | 983 (66.3%) | 499 (33.7%) |  |
 PI based | 413 (21.8%) | 275 (66.5%) | 138 (33.5%) |  |
Duration since HIV diagnosis (Months), Median (IQR) a | 62 (36.0, 92.0) | 61 (34.0, 92.0) | 64 (36.0, 94.0) | 0.231 |
Duration on ART (Months), Median (IQR)a | 57 (32.0, 84.0) | 56 (32.0, 85.0) | 60 (32.0, 82.0) | 0.382 |
CD4 count at ART initiation, Median (IQR) a | 173 (83.0, 255.0) | 197 (112.0, 297.0) | 108 (58.0, 182.0) | < 0.0001 |
CD4 count NADIR, Median (IQR) a | 146 (72.0, 235.0) | 183 (88.0, 277.0) | 88 (49.0, 165.0) | < 0.0001 |
Current/updated CD4 count, Median (IQR) a | 402 (236, 620) | 440 (286, 664) | 331 (187, 521) | < 0.0001 |
Virologic condition on ART, n (%) | < 0.0001 | |||
 Virologic failure (VF) | 297 (15.6%) | 166 (55.9%) | 131 (44.1%) |  |
 Virologic suppression (VS) | 1607 (84.4%) | 1101 (68.5%) | 506 (31.5%) |  |
IPT on ART, n (%) | 0.001 | |||
 ART plus IPT given | 358 (18.8%) | 264 (73.7%) | 94 (26.3%) |  |
 ART alone | 1546 (81.2%) | 1003 (64.9%) | 543 (35.1%) |  |